Natural sources of antidyslipidaemic agents: Is there an evidence-based approach for their prescription?

Mediterranean Journal of Nutrition and Metabolism

Volumn 1, Issue 2, 2008, Pages 85-93

  Cicero, Arrigo F G ^a   Ertek, Sibel ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UFUK UNIVERSITY   (Turkey)

Author keywords

Complementary medicine; Dietary supplements; Dyslipidaemia; Efficacy; Herbal; Nutraceuticals; Remedies

Indexed keywords

EID: 77649113271     PISSN: 1973798X     EISSN: 19737998     Source Type: Journal    
DOI: 10.3233/s12349-008-0011-6     Document Type: Article

References (60)

1. Bean WB (1968) Sir William Osler: Aphorism from his bedside teaching and writing. Thomas, Springfield, IL, p 105
2. Capasso L (1998). 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet, 352: 1864.
3. Goldman P (2001). Herbal medicine today and the roots of modern pharmacology. Ann Intern Med, 135: 594-600.
4. Rees L, Weil A (2001). Integrated medicine. BMJ, 322: 119-120.
5. Astin JA (1998). Why patients use alternative medicine. JAMA, 279: 1548-1553.
6. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285: 2486-2497.
7. Anderson JW, Allgood LD, Lawrence A et al (2000). Cholesterollowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr, 71: 472-479.
8. Sierra M, Garcia JJ, Fernandez N et al (2002). Therapeutic effects of psyllium in type 2 diabetic patients. Eur J Clin Nutr, 56: 830-842.
9. Wolever TM, Jenkins DJ, Mueller S et al (1994). Method of administration influences the serum cholesterol-lowering effect of psyllium. Am J Clin Nutr, 59: 1055-1059.
10. Petchetti L, Frishman WH, Petrillo R, Raju K (2007). Nutriceuticals in cardiovascular disease: psyllium. Cardiol Rev, 15: 116-122.
11. Moreyra AE, Wilson AC, Koraym A (2005). Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med, 165: 1161-1166.
12. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (1999). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet, 354: 447-455.
13. Bucher HC, Hengstler P, Schindler C, Meier G (2002). N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med, 112: 298-304.
14. Borghi C, Cicero AF (2007). Blood pressure modulating properties of omega-3 polyunsaturated fatty acids (PUFA). Another PUFA heart protective effect? High Blood Pressure Cardiovasc Prevent, 14: 55-61.
15. Sirtori CR, Lovati MR (2001). Soy proteins and cardiovascular disease. Curr Atheroscler Rep, 3: 47-53.
16. Anderson JW, Johnstone BM, Cook-Newell ME (1995). Metaanalysis of the effects of soy protein intake on serum lipids. N Engl J Med, 333: 276-282.
17. Cicero AF, Fiorito A, Panourgia MP et al (2002). Effects of a new soy/beta-sitosterol supplement on plasma lipids in moderately hypercholesterolemic subjects. J Am Diet Assoc, 102: 1807-1811.
18. Grundy SM (2005) Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 96(1A): 47D-50D
19. Law M (2000). Plant sterols and stanols margarines and heath. BMJ, 320: 861-864.
20. Hallikainen MA, Sarkkinen ES, Gylling H et al (2000). Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr, 54: 715-725.
21. Patch CS, Tapsell LC, Williams PG, Gordon M (2006). Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. Vasc Health Risk Manag, 2: 157-162.
22. Plat J, Mensink RP (2005) Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 96(1A): 15D-22D
23. Earnest CP, Mikus CR, Lemieux I et al (2007). Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease. Nutrition, 23: 625-633.
24. McKenney J (2004). New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med, 164: 697-705.
25. Levy DR, Pearson TA (2005). Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clin Cardiol, 28: 317-320.
26. McCormack PL, Keating GM (2005). Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs, 65: 2719-2740.
27. Xu G, Huang X, Qiu L et al (2007) Mechanism study of chitosan on lipid metabolism in hyperlipidemic rats. Asia Pac J Clin Nutr 16[Suppl 1]: 313-317
28. Ylitalo R, Lehtinen S, Wuolijoki E et al (2002). Cholesterol-lowering properties and safety of chitosan. Arzneimittelforschung, 52: 1-7.
29. Lehtimaki T, Metso S, Ylitalo R et al (2005). Microcrystalline chitosan is ineffective to decrease plasma lipids in both apoprotein E epsilon 4 carriers and non-carriers: a long-term placebo-controlled trial in hypercholesterolemic volunteers. Basic Clin Pharmacol Toxicol, 97: 98-103.
30. Rabinovitz H, Friedensohn A, Leibovitz A et al (2004). Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. Int J Vitam Nutr Res, 74: 178-182.
31. Broadhurst CL, Domenico P (2006). Clinical studies on chromium picolinate supplementation in diabetes mellitus-a review. Diabetes Technol Ther, 8: 677-687.
32. Sirtori CR, Calabresi L, Ferrara S et al (2000). L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis, 10: 247-251.
33. Derosa G, Cicero AF, Gaddi A et al (2003). The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther, 25: 1429-1439.
34. Gunes B, Yalcin SS, Kalkanoglu HS et al (2005). The effect of oral carnitine supplementation on the lipid profiles of hyperlipidemic children. Acta Pediatr, 9: 711-716.
35. Mason P (2002) Dietary supplements. Pharmaceutical Press, London
36. Cicero AF, Derosa G, Miconi A et al (2005) Treatment of massi-ve hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? Biofactors 23: 7-14
37. Littarru GP, Langsjoen P (2007). Coenzyme Q and statins: biochemical and clinical implications. Mitochondrion, 7:S168-S174.
38. Cicero AF, Brancaleoni M, Laghi L et al (2005). Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med, 13: 273-278.
39. Keithley JK, Swanson B, Sha BE et al (2002). A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition, 18: 201-204.
40. Gheith O, Sheashaa H, Abdelsalam M et al (2008). Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin Exp Nephrol, 12: 189-194.
41. Chen JT, Wesley R, Shamburek RD et al (2005). Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy, 25: 171-183.
42. Berthold HK, Unverdorben S, Degenhardt R et al (2006). Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA, 295: 2262-2269.
43. Dulin MF, Hatcher LF, Sasser HC, Barringer TA (2006). Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr, 84: 1543-1548.
44. Cicero AF, Derosa G (2005). Rice bran and its main components: potential role in the management of cardiovascular disease risk. Curr Topics Nutraceut Res, 3: 29-46.
45. Cicero AF, Martini C, Fiorito A, Gaddi A (2001). Case problem: dietary treatment for children with hyperlipidemia. J Am Diet Assoc, 101: 693-696.
46. Kong W, Wei J, Abidi P et al (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 10: 1344-1351.
47. Doggrell SA (2005). Berberine-a novel approach to cholesterol lowering. Expert Opin Investig Drugs, 14: 683-685.
48. Cicero AF, Rovati L, Setnikar I (2007). Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. Arzneimittelforschung, 57: 26-30.
49. Borek C (2006). Garlic reduces dementia and heart-disease risk. J Nutr, 136: 810S-812S.
50. Ackermann RT, Mulrow CD, Ramirez G et al (2001). Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med, 161: 813-824.
51. Gardner CD, Lawson LD, Block E et al (2007). Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med, 26: 167: 346-353.
52. Thompson Coon JS, Ernst E (2003). Herbs for serum cholesterol reduction. A systematic review. J Fam Pract, 52: 468-478.
53. Tokunaga S, White IR, Frost C et al (2002). Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol, 12: 157-165.
54. Ulbricht C, Basch E, Szapary P et al (2005). Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med, 13: 279-290.
55. Buettner C, Yeh GY, Phillips RS et al (2006). Systematic review of the effects of ginseng on cardiovascular risk factor. Ann Pharmacother, 39: 83-95.
56. Cicero AF, Vitale G, Savino G, Arletti R (2003). Notoginsenoides effects on fibrinogen and lipid plasmatic level in rat submitted to a new model of fat diet. Phytother Res, 17: 174-178.
57. Adams KE, Cohen MH, Eisenberg D, Jonsen AR (2002). Ethical considerations of complementary and alternative medical therapies in conventional medical settings. Ann Intern Med, 137: 660-664.
58. Gray CM, Tan AW, Pronk NP, O’Connor PJ (2002). Complementary and alternative medicine use among health plan members. A cross-sectional survey. Eff Clin Pract, 5: 17-22.
59. Eisenberg DM, Kessler RC, Van Rompay MI et al (2001). Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med, 135: 344-351.
60. Owen DK, Lewith G, Stephens CR (2001) Can doctors respond to patients’ increasing interest in complementary and alternative medicine? BMJ 322: 154-158